Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

ResMed appoints CEO: Kieran T. Gallahue will take the top spot at the sleep and respiratory device firm and join the board of directors on Jan. 1, 2008. Gallahue, who is being promoted to the position from his role as president and chief operating officer of ResMed Global, succeeds company founder Peter C. Farrell. Before Gallahue joined ResMed in 2003 as president and COO of the Americas, he served as president of diagnostics firm Nanogen. Farrell will continue as executive chairman of the board until June 30, 2008, when he will become non-executive chairman...

You may also be interested in...



People In Brief

Cooper cuts exec, seeks CEO: Robert Weiss, Cooper Companies' chief operating officer, gains responsibilities as president of CooperVision, replacing current president Gregory Fryling who leaves after 22 years at the firm. The changes are part of Cooper's continuing integration of Ocular Sciences, acquired in January 2005, as it combines its CooperVision and Cooper Companies headquarters (1"The Gray Sheet" June 12, 2006, p. 15). Weiss joined Cooper in 1977 and served as CFO from 1989 until he became COO in 2005. Prudential Equity Group analyst Larry Biegelsen has pegged Weiss as a potential successor to CEO Thomas Bender, who plans to relinquish the role, which he has held since 1995, by year-end. Cooper says it is considering both internal and external candidates...

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel